NMC Health plc revised earnings guidance for the year 2018 and 2019. The company provided an update on guidance given in January, following positive developments in the second half of 2018. The company now anticipated an increase of 2% in revenue growth from 22% to 24% and an increased EBITDA guidance from $465 million to $480 million by year-end 2018. 2019 guidance will also point towards continuation of strong organic growth on the back of sustained ramp-up at key facilities, integration and expansion of acquired entities as well as strong operational performance. Revenues are forecast to increase by 22%-24% and EBITDA is expected to increase by 18%-20%. 2019 guidance does not include the effects of implementation of IFRS 16. The guidance also does not reflect the impact of anticipated financial consolidation of National Medical Care Company. During the year 2019, management also anticipates: 1) opening of new greenfield facilities, particularly in UAE, 2) continued ramp-up of various facilities across multiple geographies and 3) full-year consolidation of Aspen Healthcare, all of which will impact EBITDA margin. Management remains confident on the longer-term margin guidance for the Company and NMC remains on track to achieve 25% EBITDA margin by 2020/2021.